In this captivating episode, David engages in a thought-provoking conversation with none other than Joshua White, the visionary CEO behind the Fireside Project. This groundbreaking initiative has ushered in a new era of support and safety within the realm of psychedelics, as it introduces the world's first real-time psychedelic peer support line.
In today’s episode, we will be covering some Massive MindMed news that broke on January 14th that lead me to believe that MindMed might be expanding to psilocybin.
Mindmed stock, MMED on the Canadian NEO market, and MMEDF on the American OTC market led with a press release entitled “MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience”. MindMed revealed that the company has added a scientist named Robert Barrow as their Chief Development Officer.
Tucked away in this news release about a hiring decision is a quote which points to a future MindMed project
And that project will be researching the effects of Psilocybin
So up until now, MindMed has focused all their phase 2 trials on LSD and 18-MC, which is a derivative of Ibogaine, while leaving treating maladies with psilocybin to other companies like Compass Pathways (NASDAQ:CMPS).
So, Barrow is bringing with him to MindMed intimate knowledge about the efficacy of psilocybin in treating MDD, as well as dosing data and regime set up.
MindMed (MMED/MMEDF) has some phase 1 trials looking at the safety of psilocybin in conjunction with the Liechti Lab at the University Hospital Basel
and is also comparing psilocybin to LSD in a phase 1 trial. MindMed also has a licence to test psilocybin. However, MindMed has yet to start a trial specifically looking at psilocybin as a medicine..
So does this mean that MindMed’s hiring decision is related to the company’s plans on expanding their clinical trial pipeline to include a psilocybin treatment, sometime in the future? If that speculation turns out to be true, that decision will further expand MindMed’s potential product pipeline as well as the MindMed stock.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
https://www.businesswire.com/news/home/20190905005528/en/Usona-Institute-Clinical-Trial-Psilocybin-Major-Depressive
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMED #MMEDF
During our time at Wonderland Miami, $PSYC CEO, David Flores,…
CEO of Mindset Pharma, James Lanthier, gives us an overview of his company and the 4 new psychedelics they are creating. He also discusses some big breaking news!
In this episode, Matthew and Paul discuss The Psychedelic Institute’s aspirations with the launch of the Awakening of Consciousness Conference, the differences between legalization and decriminalization, and the importance of being brave, and thinking outside the box in understanding what it takes to make the most of one’s own experience of sacred plant medicines.
Today we are going to be talking about MindMed’s, (MNDM : NASDAQ), (MMED : NEO) patent application made in collaboration with BioXcel Therapeutics.
BioXcel is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology.
The Patent is “for detecting and preventing the early onset of agitation in patients predisposed to highly agitated behaviour”.
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#mindmed #mmed #mnmdstock
Tim Moore, CEO of Havn Life discusses how he is leveraging his past experience in the cannabis industry to create an effective path to success for Havn Life.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
